Compare GLP-1 Weight Loss Medications
Make informed decisions with detailed, evidence-based comparisons of all available GLP-1 medication options.
Understanding Your Options
With multiple GLP-1 medications available, choosing the right one can feel overwhelming. This hub provides comprehensive comparisons to help you understand the differences in efficacy, side effects, dosing schedules, and costs.
In-Depth Comparisons
Semaglutide vs. Tirzepatide: Head-to-Head Comparison
Comprehensive comparison of efficacy, side effects, dosing, and cost between the two leading GLP-1 medications.
GLP-1s vs. Traditional Weight Loss Methods
How GLP-1 medications compare to diet, exercise, and other weight loss interventions in terms of effectiveness.
Brand Name vs. Compounded GLP-1s
Understanding the differences between FDA-approved medications and compounded alternatives including safety and cost.
Cost Comparison: All GLP-1 Options
Detailed breakdown of costs across all available GLP-1 medications and how to find the most affordable option.
Best GLP-1 for Weight Loss: 2025 Rankings
Compare semaglutide, tirzepatide, and other GLP-1 medications. Updated 2025 rankings based on clinical data, cost, and real-world results.
Quick Comparison Overview
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Average Weight Loss | 15-17% | 20-22% |
| Dosing Frequency | Once weekly | Once weekly |
| Mechanism | GLP-1 agonist | GLP-1/GIP dual agonist |
| Average Cost/Month | $900-1,200 | $1,000-1,500 |
| Common Side Effects | Nausea, diarrhea | Nausea, diarrhea |
Find Your Perfect Match
Talk to a Trimi healthcare provider to determine which GLP-1 medication is best suited for your unique needs and health goals.
Get Personalized RecommendationsMedical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).